References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailImpact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.
Bruyère, Olivier ULg; Scholtissen, S.; Neuprez, Audrey et al

in Journal of Medical Economics (2009), 12(4), 356-360

Abstract Objectives: The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA ... [more ▼]

Abstract Objectives: The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses. Methods: Data from the STOPP study was used. This study was a randomised, double-blind, placebo (PL) -controlled trial of 2-year duration. In the STOPP study, authors assessed quality of life using the Western Ontario and McMaster Osteoarthritis Index (WOMAC). WOMAC scores were translated into Health Utility Index (HUI) scores using a specific formula. Incremental cost effectiveness ratio (ICER) was calculated taking into account the cost of CS and its effect on HUI scores, compared to PL. Results: At baseline, the mean (SD) HUI scores were 0.59 (0.17), and 0.59 (0.18) for the PL and CS groups, respectively (p=0.31 between the two groups). The mean (SD) HUI scores changes from baseline to 6 months were 0.02 (0.02), and 0.05 (0.01) for the PL and CS groups, respectively (p=0.03). After 24 months of follow-up, HUI score increases by 0.04 (0.02) in the PL group and by 0.05 (0.02) in the CS group (p=0.37). Using the price bracket of CS in Europe, ICER assessment always resulted in a cost below euro30,000 per QALY gained, after 6, 12 and 24 months of treatment. Conclusion: CS treatment increases health utilities in patients with knee OA compared to PL over the first 6 months of treatment. Economic evaluation based on these data suggests that CS treatment could be considered as cost-effective in patients with knee OA up to a period of 24 months. A limitation in this study is the absence of direct utility assessment as well as the absence of effective treatment as comparator. [less ▲]

Detailed reference viewed: 64 (18 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: new data on fracture prevention and mechanisms of action.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Neuprez, Audrey et al

in Current Osteoporosis Reports (2009), 7(3), 96-102

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence ... [more ▼]

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its anti-fracture efficacy at various skeletal sites has been established for as long as 5 years through studies of the highest methodological standards. Increases in bone mineral density observed after 1 year of treatment are predictive of the long-term fracture efficacy, suggesting for the first time in osteoporosis that bone densitometry can be used as a monitoring tool. Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis. [less ▲]

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailLoss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.
Bruyère, Olivier ULg; Varela, A. R.; Adami, S. et al

in European journal of epidemiology (2009), 24

The objective of the study assess the relationship between bone mineral density (BMD) loss over time and fracture incidence in postmenopausal women. This is a posthoc analysis that includes women from the ... [more ▼]

The objective of the study assess the relationship between bone mineral density (BMD) loss over time and fracture incidence in postmenopausal women. This is a posthoc analysis that includes women from the placebo group of two large randomized controlled trials having assessed the efficacy of a new anti-osteoporotic drug. BMD was assessed every 6 months during 3 years at the lumbar spine, the femoral neck and the total proximal femur. Vertebral fractures were assessed using a semiquantitative method. Hip fractures were based on written documentation. All patients received calcium and vitamin D. In the present study that included 1,775 patients (with complete data at baseline and after 3 years), the logistic regression analysis, adjusted for covariates, showed that 3-year change in lumbar BMD was not statistically associated with the new vertebral fractures after 3 years. However, femoral neck and total proximal femur BMD changes was statistically correlated with the incidence of new vertebral fractures (P < 0.001). When considering change in BMD after the first year of follow-up, a decrease in total proximal femur BMD was statistically associated with an increase in the incidence of new vertebral fractures during the last 2 years of follow-up (P = 0.048). The 3-year change in femoral neck and total proximal BMD was statistically correlated with the incidence of hip and fragility fracture after 3 years (all P < 0.001). In this elderly osteoporotic population receiving calcium and vitamin D, a decrease in hip BMD after 1 or 3 year of follow-up, is associated with an increased risk of fracture incidence. However, spine BMD changes do not influence vertebral fracture incidence. [less ▲]

Detailed reference viewed: 41 (10 ULg)
Full Text
Peer Reviewed
See detailBone mineral density and health related quality of life: a 3-year follow-up study of osteoportic postmenopaul women
Bruyère, Olivier ULg; De Cock, Caroline; Deroisy, Rita ULg et al

in The Open Geritric Medicine Journal (2009), 2

Objective: The objective of this study was to evaluate the relationship between change in bone mineral density (BMD) and change in health related quality of life (HRQoL) over a 3-year eriod, in patients ... [more ▼]

Objective: The objective of this study was to evaluate the relationship between change in bone mineral density (BMD) and change in health related quality of life (HRQoL) over a 3-year eriod, in patients without incident of osteoporotic fracture. Materials and Methods: Prior to the present study, two randomized controlled trials had been carried out to assess the efficacy of a new anti-osteoporotic drug. From the placebo group of those two trials, we selected for the present study 1838 osteoporotic postmenopausal women aged over 50 years, and followed their progress for a period of 3 years. BMD was measured at the lumbar spine and the proximal femur by dual-energy X-ray absorptiometry. Each patient received calcium and vitamin D supplements. HRQoL was assessed using 2 questionnaires: the generic tool Short Form 36 items (SF-36; including mental and physical components) and the specific Quality of Life Questionnaire in Osteoporosis (QUALIOST). Result: At baseline, after adjustment for body mass index (BMI), age, number of vertebral fractures and number of peripheral fractures, multivariate regression analysis showed a significant association between the lumbar BMD and the mental component of the SF-36 (p<0.001). However, the relationship was not significant with the global score of the QUALIOST (p=0.098) and the physical component of the SF-36 (p=0.051). Multivariate regressions did not show a significant relationship between HRQoL and proximal femur BMD at baseline. After 3 years of follow-up, multivariate regression analysis showed no significant association between change in lumbar BMD and the main HRQoL items (global score of the QUALIOST, physical and mental components of the SF-36; p between 0.437 and 0.942). No significant relationships were found between change in femoral BMD and change in the global score of the QUALIOST (p=0.088) or change in the mental component of the SF-36 (p=0.222). However, a significant positive association (p=0.031) appeared between change in the physical component of the SF-36 and femoral BMD change. Conclusion: In osteoporotic postmenopausal women receiving calcium and vitamin D, few relationships were found between BMD and HRQoL. However, these results were not strong enough to indicate a real clinically interesting relationship between HRQoL and BMD. Other studies would need to be performed to verify these results. [less ▲]

Detailed reference viewed: 57 (4 ULg)
Full Text
Peer Reviewed
See detailDevelopment and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Value in Health (2009), 12(5), 687-696

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼]

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲]

Detailed reference viewed: 234 (35 ULg)
Full Text
Peer Reviewed
See detailAssessment of determinants for osteoporosis in elderly men.
Scholtissen, Sophie ULg; Guillemin, F.; Bruyère, Olivier ULg et al

in Osteoporosis International (2009), 20(7), 1157-66

SUMMARY: The aim of this cross-sectional study was to determine and quantify some determinants associated to low bone mineral density (BMD) in elderly men. This study showed that ageing, a lower body mass ... [more ▼]

SUMMARY: The aim of this cross-sectional study was to determine and quantify some determinants associated to low bone mineral density (BMD) in elderly men. This study showed that ageing, a lower body mass index (BMI), a higher blood level of C-terminal cross-linking telopeptides of type I collagen (CTX-1), family history of osteoporosis, and/or fracture and prior fracture were associated with bone mineral density. INTRODUCTION: Our aims were to identify some determinants associated to low bone mineral density in men and to develop a simple algorithm to predict osteoporosis. METHODS: A sample of 1,004 men aged 60 years and older was recruited. Biometrical, serological, clinical, and lifestyle determinants were collected. Univariate, multivariate, and logistic regression analyses were performed. Receiver operating characteristic analysis was used to assess the discriminant performance of the algorithm. RESULTS: In the multiple regression analysis, only age, BMI, CTX-1, and family history of osteoporosis and/or fracture were able to predict the femoral neck T-score. When running the procedure with the total hip T-score, prior fracture also appeared to be significant. With the lumbar spine T-score, only age, BMI, and CTX-1 were retained. The best algorithm was based on age, BMI, family history, and CTX-1. A cut-off point of 0.25 yielded a sensibility of 78%, a specificity of 59% with an area under the curve of 0.73 in the development and validation cohorts. CONCLUSION: Ageing, a lower BMI, higher CTX-1, family history, and prior fracture were associated with T-score. Our algorithm is a simple approach to identify men at risk for osteoporosis. [less ▲]

Detailed reference viewed: 81 (8 ULg)
Full Text
Peer Reviewed
See detailThe need for economic evaluation in osteoarthritis
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Aging Health (2009), 5(5), 591-594

Detailed reference viewed: 40 (7 ULg)
Full Text
Peer Reviewed
See detailImpact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2008, December), 19(S2), 282

Detailed reference viewed: 38 (13 ULg)
Full Text
Peer Reviewed
See detailCost-utility of calcium and vitamin D supplementation in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, December), 19(S2), 363

Detailed reference viewed: 28 (8 ULg)
See detailDebates on osteoporosis management
Bruyère, Olivier ULg

Conference (2008, October 18)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailDéficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques
DeCock, Caroline; Bruyère, Olivier ULg; Collette, Julien ULg et al

in Revue du Rhumatisme (2008), 75

Objectif. – Des études antérieures ont démontré qu’un faible taux sanguin de vitamineD peut entraîner un hyperparathyroïdisme secondaire, qui augmente la fragilité osseuse et, de ce fait, le risque de ... [more ▼]

Objectif. – Des études antérieures ont démontré qu’un faible taux sanguin de vitamineD peut entraîner un hyperparathyroïdisme secondaire, qui augmente la fragilité osseuse et, de ce fait, le risque de fractures, particulièrement chez les sujets âgés de plus de 50 ans. Le but de ce travail est d’évaluer le niveau d’insuffisance en vitamine D chez les femmes franc¸aises ménopausées. Méthodes. – Nous avons mesuré la vitamine D (25OHD) sérique chez 1292 femmes franc¸aises ménopausées ostéoporotiques ou ostéopéniques, âgées de 52 à 94 ans. Dans cette population, 26,5% des patientes consommaient un complément de vitamine D. Quatre valeurs seuil de 25OHD ont été retenues sur base des données de la littérature : 30, 50, 75 et 80 nmol/l (< 12, < 20, < 30 ou < 32 ng/ml). Résultats. – Le taux sérique moyen de 25OHD était de 51,54±26,14 nmol/l [∼20,62 (∼10,46) ng/ml]. Trois cent quarante-trois patientes recevaient une supplémentation en vitamine D, associée ou non à du calcium. Celles-ci présentaient une concentration sérique moyenne de 25OHD supérieure à celle des non-consommatrices [65,09 nmol/l (∼26,04 ng/ml) versus 46,63 nmol/l (∼18, 65 ng/ml) ; p < 0,001]. Chez les patientes non supplémentées en vitamine D, le taux de prévalence de l’insuffisance en vitamineD était de 27,3 ; 54,1 ; 89,9 et 93,2% selon qu’on utilisait les seuils de 30, 50, 75 ou 80 nmol/l (∼12, 20, 30 ou 32 ng/ml). Le niveau moyen de 25OHD variait également suivant la saison au cours de laquelle la mesure avait été effectuée (p < 0,001). Ainsi, la valeur moyenne la plus élevée a été observée en été [53,41 (18,79) nmol/l (∼21,36 (7,52) ng/ml)]. Conclusion. – Cette étude met en évidence une prévalence élevée de l’insuffisance en vitamineD chez les femmes franc¸aises ménopausées ostéoporotiques ou ostéopéniques. [less ▲]

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailPlace of residence as a risk factor for hip fracture? A case-control 3-year study
Bruyère, Olivier ULg; Pieck, C.; Hiligsmann, Mickaël ULg et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 428

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in institutionalized osteoporotic postmenopausal women
Bruyère, Olivier ULg; Delhez, M.; Collette, Julien ULg et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 403

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailAssociation between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study
Bruyère, Olivier ULg; Roces-Varela, A.; Adami, Silvio et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 89

Detailed reference viewed: 11 (6 ULg)